Preparing method for ambroxol salbutamol lipid solid dispersion

A technology of ambroxolbuterol and solid dispersion, applied in the field of ambroxol salbutamol lipid solid dispersion and preparation thereof, can solve the problems such as no reports of lipid solid dispersion, and achieves the treatment of respiratory system diseases and stable quality , the effect is remarkable

Inactive Publication Date: 2016-03-23
CP PHARMA QINGDAO CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Dosage forms such as solutions and granules containing ambroxol hydrochloride and salbutamol sulfate already exist in the prior art, but there is no report of lipid solid dispersion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparing method for ambroxol salbutamol lipid solid dispersion
  • Preparing method for ambroxol salbutamol lipid solid dispersion
  • Preparing method for ambroxol salbutamol lipid solid dispersion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:1000 Add to the molten lipid carrier, vortex, ultrasonic for 30min to dissolve evenly, to obtain the lipid mixture, add the lipid mixture in the molten state to the solid carrier whose mass is 1:2 with the lipid carrier to absorb and solidify .

Embodiment 2

[0022] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:1500 Add to the molten lipid carrier, vortex and ultrasonic for 30 minutes to dissolve evenly to obtain a lipid mixture, add the lipid mixture in a molten state to a solid carrier with a mass of lipid carrier of 1:3 to absorb and solidify .

Embodiment 3

[0024] Mix 25% glyceryl trilaurate, 30% coconut oil, 15% polyethylene glycol caprylic acid / capric glyceride, 20% vitamin E acetate and 10% PEG200 to obtain a lipid carrier, 30% micropowder silica gel and Mix 70% cornstarch uniformly to obtain a solid carrier, pulverize 15g of ambroxol hydrochloride and 20g of salbutamol sulfate through a 120 mesh sieve, add 5g of butylated hydroxyanisole and mix uniformly to obtain a drug mixture, and the drug mixture is in a mass ratio of 1:2000 Add to the molten lipid carrier, vortex and ultrasonic for 30 minutes to dissolve evenly to obtain a lipid mixture, add the lipid mixture in a molten state to a solid carrier with a mass ratio of 1:4 to the lipid carrier to absorb and solidify .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to ambroxol salbutamol lipid solid dispersion and a preparing method thereof and belongs to the field of medicinal preparations. The lipid solid dispersion is prepared from ambroxol hydrochloride, salbutamol sulfate and butylated hydroxyanisole, a lipid carrier is a mixture comprising 25% of glycerol trilaurate, 30% of coconut oil, 15% of polyethylene glycol octanoic acid/caprin, 20% of vitamin E acetic ester and 10% of PEG 200, and a solid carrier is a mixture comprising 30% of superfine silica powder and 70% of corn starch. Quality is stable, the effect is significant, and the ambroxol salbutamol lipid solid dispersion can effectively treat respiratory diseases such as acute and chronic bronchitis and asthma.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an ambroxoxalbutamol lipid solid dispersion and a preparation method thereof. Background technique [0002] Respiratory system disease is a common and frequently-occurring disease. The main lesions are in the trachea, bronchi, lungs, and chest cavity. Mild cases often cause coughing, chest pain, and respiratory problems. Severe cases have dyspnea, hypoxia, and even death due to respiratory failure. The death rate in the city is the third, while in the countryside it is the first. What should be paid more attention to is that due to air pollution, smoking, population aging and other factors, chronic obstructive pulmonary disease (referred to as COPD, including chronic bronchitis, emphysema, pulmonary heart disease), bronchial asthma, lung cancer, etc. , Pulmonary diffuse interstitial fibrosis, and the morbidity and mortality of diseases such as pulmonary infection are i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/127A61K31/137A61K47/08A61K47/34A61K47/36A61P11/06A61P11/00A61K47/14
CPCA61K9/127A61K31/137A61K47/08A61K47/34A61K47/36A61K2300/00
Inventor 王明刚陈阳生任莉
Owner CP PHARMA QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap